Wave Life Sciences reports preliminary $602M cash; outlines 2026 pipeline milestones

Wave Life Sciences Ltd.

Preliminary unaudited cash $602M as of Dec 31, 2025; runway into 3Q 2028.
WVE-007 Phase 2a multidose for obesity to start 1H 2026; 400mg 3-mo & 240mg 6-mo data due Q1 2026.
WVE-006 400mg multidose data from RestorAATion-2 expected Q1 2026; CTA for WVE-008 in 2026.
NDA filing for WVE-N531 (DMD exon 53 skipping) on track for 2026.
Plan to submit IND for WVE-003 (Huntington's) with prospective strategic partner.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.